Entera Bio Ltd. - Ordinary Shares (ENTX)
ENTX moved a median of 0.00% 30 minutes after news, and -1.06% by the close. How ENTX actually reacts to news — the realized, point-in-time move the market made, measured across 217 labeled events over the last three years with zero look-ahead.
ENTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 39% | 204 |
| 30-min | 0.00% | 46% | 216 |
| 60-min | -0.01% | 43% | 217 |
| to close | -1.06% | 37% | 204 |
| Middle 50% of ENTX reactions | -2.30% to +1.52% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 217 |
Half of all Entera Bio Ltd. - Ordinary Shares news events land between -2.30% and +1.52% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ENTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ENTX's baseline. Nothing else.
Recent ENTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form DEF 14A Entera Bio Ltd. For: Oct 14 | SEC filing · Form DEF | SEC EDGAR | +0.80% | +11.24% | |
| Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting | Press release | GlobeNewswire | +0.00% | -6.04% | |
| Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting | Press release | GlobeNewswire | +0.20% | +0.81% | |
| Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise | Press release | GlobeNewswire | -1.50% | -4.89% | |
| Form 8-K Entera Bio Ltd. For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -1.50% | -4.89% | |
| Form PRE 14A Entera Bio Ltd. For: Sep 23 | SEC filing · Form PRE | SEC EDGAR | +3.60% | +0.72% | |
| Form EFFECT Entera Bio Ltd. | SEC filing · Form EFFECT | SEC EDGAR | +0.99% | -2.64% | |
| Correction: Entera to Participate in Upcoming Fall Investor Conferences | Press release | GlobeNewswire | +0.31% | -4.94% | |
| Entera to Participate in Upcoming Fall Investor Conferences | Press release | GlobeNewswire | -1.56% | -3.75% | |
| Form S-3 Entera Bio Ltd. | SEC filing · Form S-3 | SEC EDGAR | -1.13% | +4.27% | |
| Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation | Press release | GlobeNewswire | +0.35% | +0.00% | |
| Form 8-K Entera Bio Ltd. For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | +0.35% | +0.00% | |
| Form D Entera Bio Ltd. | SEC filing · Form D | SEC EDGAR | -0.69% | -3.45% | |
| Entera Announces Second Quarter 2026 Financial Results and Business Updates | Press release | GlobeNewswire | -1.76% | — | |
| Form 10-Q Entera Bio Ltd. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.76% | — | |
| Form 8-K Entera Bio Ltd. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -1.76% | — | |
| Form S-8 Entera Bio Ltd. | SEC filing · Form S-8 | SEC EDGAR | -1.76% | — | |
| Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting | Press release | GlobeNewswire | +2.08% | -0.69% | |
| Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference | Press release | GlobeNewswire | -0.34% | +1.72% | |
| Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE | Press release | PR Newswire | +0.98% | -2.28% | |
| Form 8-K Entera Bio Ltd. For: Jul 26 | SEC filing · Form 8-K | SEC EDGAR | -1.23% | -7.97% | |
| Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement | Press release | GlobeNewswire | -3.75% | +33.79% | |
| Form 8-K Entera Bio Ltd. For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.50% | |
| Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis | Press release | GlobeNewswire | -0.81% | +19.36% | |
| Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026 | Press release | GlobeNewswire | +0.00% | -2.48% | |
| ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis) | Press release | GlobeNewswire | -1.60% | -3.20% | |
| Form ARS Entera Bio Ltd. For: Jun 03 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +1.67% | |
| Form DEF 14A Entera Bio Ltd. For: Jun 03 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +1.67% | |
| Form DEFA14A Entera Bio Ltd. | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +1.67% | |
| Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation | Press release | GlobeNewswire | +0.83% | +1.67% | |
| Form EFFECT Entera Bio Ltd. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -0.81% | |
| Form PRE 14A Entera Bio Ltd. For: May 14 | SEC filing · Form PRE | SEC EDGAR | +0.00% | -3.08% | |
| Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs | Press release | GlobeNewswire | -1.60% | -6.40% | |
| Form 10-Q Entera Bio Ltd. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.60% | -6.40% | |
| Form 8-K Entera Bio Ltd. For: May 08 | SEC filing · Form 8-K | SEC EDGAR | -1.60% | -6.40% | |
| Form S-3 Entera Bio Ltd. | SEC filing · Form S-3 | SEC EDGAR | -1.60% | -6.40% | |
| Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613 | Press release | GlobeNewswire | +1.77% | +0.00% | |
| Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners | Press release | PR Newswire | +0.46% | -1.65% | |
| Form 8-K Entera Bio Ltd. For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | -0.79% | -5.56% | |
| Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds | Press release | GlobeNewswire | -0.42% | +5.88% | |
| Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +3.55% | -1.96% | |
| Form 10-K Entera Bio Ltd. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +3.55% | -1.96% | |
| Form 8-K Entera Bio Ltd. For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +3.55% | -1.96% | |
| Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis | Press release | GlobeNewswire | +3.03% | -1.51% | |
| Form 8-K Entera Bio Ltd. For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | +3.03% | -1.51% | |
| Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference | Press release | GlobeNewswire | +0.00% | -2.58% | |
| Entera Bio Announces Open Market Purchases of Company Stock by Board Members | Press release | GlobeNewswire | +5.33% | +9.33% | |
| Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones | Press release | GlobeNewswire | +7.48% | +24.30% | |
| Form 8-K Entera Bio Ltd. For: Feb 04 | SEC filing · Form 8-K | SEC EDGAR | +7.48% | +24.30% | |
| Form 8-K Entera Bio Ltd. For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | +0.39% | -6.25% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ENTX section they belong to.
Where else ENTX is measured.
ENTX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| AngioDynamics, Inc. (ANGO) | 218 | +0.33% | 54% |
| Anixa Biosciences, Inc. (ANIX) | 217 | 0.00% | 49% |
| Precipio, Inc. (PRPO) | 217 | +0.51% | 52% |
| Sensus Healthcare, Inc. (SRTS) | 217 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Entera Bio Ltd. - Ordinary Shares's median reaction calculated?
Every labeled ENTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 217 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of ENTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ENTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.